News – Page 1142 – Endpoints News

An FDA reform agenda: What would Commissioner Scott Gottlieb do in his first six months?

9 years ago

After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version

9 years ago

Arix IPO raises £100M for new biotech investments; Santhera sets up shop in Massachusetts

9 years ago

Another price-gouging CEO proves the system is broken, underscoring need for principled reform at the FDA

9 years ago

Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro

9 years ago

ArQule’s lead drug tivantinib flops again in PhIII liver cancer study

9 years ago

Sage CEO’s M&A chatter sparks a spike, and an awkward correction

9 years ago

Looking to an IPO? Rhythm raises $41M to pay for pivotal trials

9 years ago

Alkermes CEO Pops stays focused on 5461 filing plans; Shkreli gets booed at Harvard

9 years ago

With an extra $25M in hand, Dauntless maps the next stage of growth for the pipeline

9 years ago

Alexion shelves an early-stage Sanfilippo B drug, writes off $85M

9 years ago

Behind the scenes of J&J’s $30B Actelion buyout: Walkouts, Sanofi’s blunder and a $230M sweetener

9 years ago

PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy

9 years ago

Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch

9 years ago

Patent board tells CRISPR scientists to back off from a nasty fight over gene editing tech

9 years ago

Ionis bags a $75M milestone from Bayer; Inventiva garners $51M from IPO

9 years ago

No, President Trump, biopharma does not want you to deregulate drug development

9 years ago

Versant gambles $20 million on a UCSD spinout focused on NASH and fibrosis

9 years ago

Surrozen grabs $33M, joins startups looking to spark a comeback in regenerative med

9 years ago

Ardelyx touts a PhIII hyperphosphatemia success for tenapanor, looking to calm fears over diarrhea

9 years ago

Merck’s HIV drug doravirine looks solid — though far less stellar than rivals — in 1st PhIII

9 years ago

Merck’s leading PhIII BACE drug implodes in latest Alzheimer’s disaster

9 years ago

First page Previous page 1139 1140 114111421143 1144 1145 Next page Last page